

# MEDIATION ANALYSIS: A PRACTITIONER'S GUIDE

MASATHA THONGPAN 6537582 CLINICAL EPIDEMIOLOGY PROGRAM

## Annual Review Public Health 2016

#### ANNUAL Further

**Click here** to view this article's online features:

- Download figures as PPT slides
- Navigate linked references
- Download citations
- Explore related articles
  Search keywords

## Mediation Analysis: A Practitioner's Guide

#### Tyler J. VanderWeele

T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts 02115; email: tvanderw@hsph.harvard.edu

## Lancet Psychiatry 2017

#### The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysis

Daniel Freeman, Bryony Sheaves, Guy M Goodwin, Ly-Mee Yu, Alecia Nickless, Paul J Harrison, Richard Emsley, Annemarie I Luik, Russell G Foster, Vanashree Wadekar, Christopher Hinds, Andrew Gumley, Ray Jones, Stafford Lightman, Steve Jones, Richard Bentall, Peter Kinderman, Georgina Rowse, Traolach Brugha, Mark Blagrove, Alice M Gregory, Leanne Fleming, Elaine Walklet, Cris Glazebrook, E Bethan Davies, Chris Hollis, Gillian Haddock, Bev John, Mark Coulson, David Fowler, Katherine Pugh, John Cape, Peter Moseley, Gary Brown, Claire Hughes, Marc Obonsawin, Sian Coker, Edward Watkins, Matthias Schwannauer, Kenneth MacMahon, A Niroshan Siriwardena, Colin A Espie

#### Summary

**Background** Sleep difficulties might be a contributory causal factor in the occurrence of mental health problems. If this is true, improving sleep should benefit psychological health. We aimed to determine whether treating insomnia leads to a reduction in paranoia and hallucinations.









#### **Difference** Method

(biomedical science)

$$\begin{split} \mathsf{E}[\mathbf{Y} \mid \mathbf{a}, \mathbf{c}] &= \varphi_0 + \varphi_1 \mathbf{a} + \varphi_4 \mathbf{c}. \\ \mathsf{E}[\mathbf{Y} \mid \mathbf{a}, \mathbf{m}, \mathbf{c}] &= \theta_0 + \theta_1 \mathbf{a} + \theta_2 \mathbf{m} + \theta_4 \mathbf{c}. \\ \mathsf{D}\mathsf{E} &= \theta_1. \\ \mathsf{I}\mathsf{E} &= \varphi_1 - \theta_1. \end{split}$$

 $\frac{\text{Product Method}}{(\text{social science})}$   $E[Y \mid a, m, c] = \theta_0 + \theta_1 a + \theta_2 m + \theta_4 c.$   $E[M \mid a, c] = \beta_0 + \beta_1 a + \beta_2 c.$   $DE = \theta_1.$   $IE = \beta_1 \theta_2.$ 



### Covariate (c): Gender, educational level

	Insomnia (SCI-8)				Paranoia (GPTS)				Hallucinations (SPEQ)				
	Unadjusted mean		Adjusted difference* (95% CI), d†	p value*	Unadjusted mean		Adjusted difference* (95% CI), d†	p value*	Unadjusted mean		Adjusted difference* (95% CI), d†	p value*	
	Control	Treatment			Control	Treatment	-		Control	Treatment			
Week 3	12·34 (5·85)	14·96 (5·80)	2·62 (2·19 to 3·06), 0·61	<0.0001	24·63 (11·82)	22·61 (9·89)	-1·81 (-2·49 to -1·13), 0·15	<0.0001	5·06 (6·89)	4·06 (5·84)	-0·79 (-1·15 to -0·42), 0·12	<0.0001	
Week 10	13·31 (6·45)	18·08 (6·66)	4·78 (4·29 to 5·26), 1·11	<0.0001	23·84 (12·16)	21·06 (9·08)	-2·22 (-2·98 to -1·45), 0·19	<0.0001	4·89 (7·24)	3·12 (5·12)	-1·58 (-1·98 to -1·18), 0·24	<0.0001	
Week 22	14·43 (6·71)	19·27 (7·13)	4·81 (4·29 to 5·33), 1·12	<0.0001	23·84 (12·68)	20·75 (9·19)	-2·78 (-3·60 to −1·96), 0·24	<0.0001	4·71 (7·43)	2·87 (5·45)	-1·56 (-1·99 to -1·14), 0·23	<0.0001	

Data are mean (SD). At week 3, 1398 participants were in the control group and 1044 participants were in the treatment group. At week 10, 1142 participants were in the control group and 733 participants were in the treatment group. At week 22, 971 participants were in the control group and 603 participants were in the treatment group. SCI-8=Sleep Condition Indicator 8-item version. GPTS=Green et al Paranoid Thought Scales. SPEQ=Specific Psychotic Experiences Questionnaire. \*Linear mixed effects model adjusted for gender, student status, week, and interaction of week with randomisation, and including a random effect for student within university. Covariance matrix of within subject measurements was unstructured. †d is standardised effect size (Cohen's d).

#### Table 2: Primary outcome results

0

	Total effect		Direct effect		Indirect effect	Percentage mediated			
	Effect size (95% CI)	<mark>p value</mark>	Effect size (95% CI)	p value	Effect size (95% CI)	p value			
Paranoia (GPTS) outcome at week 10									
Insomnia at week 3 (SCI-8)	–2·27 (–3·03 to –1·51)	<0.0001	-1.85 (-2.66 to 1.04)	<0·0001	-0.67 (-0.86 to -0.48)	<0.0001	29.5%		
Insomnia at week 10 (SCI-8)	-2·27 (-3·03 to -1·51)	<0.0001	-0·97 (-1·80 to -0·14)	<0.0001	-1·31 (-1·60 to -1·02)	<0.0001	57·8%		
Hallucinations (SPEQ) outcome at week 10									
Insomnia at week 3 (SCI-8)	-1.60 (-2.00 to -1.20)	<0.0001	-1·36 (-1·79 to -0·94)	<0.0001	-0.33 (-0.43 to -0.23)	<0.0001	20.7%		
Insomnia at week 10 (SCI-8)	-1.60 (-2.00 to -1.20)	<0.0001	-0·90 (-1·34 to -0·46)	<0.0001	-0.62 (-0.78 to -0.46)	<0.0001	38.6%		

Total n=1718. GPTS=Green et al Paranoid Thought Scales. SCI-8=Sleep Condition Indicator 8-item version. SPEQ=Specific Psychotic Experiences Questionnaire. \*Outcome and mediators modelled by means of linear mixed effects models and the total, direct, and indirect effects determined using the Baron and Kenny<sup>31</sup> approach. The effect size is the adjusted treatment difference (ie, non-standardised treatment difference).

Table 3: Mediation analysis\* results

## CONFOUNDING ASSUMPTION

Assumption 1: Control Exposure -> Outcome Assumption 2: Control Mediator -> Outcome Assumption 3: Control Exposure -> Mediator Assumption 4: No Exposure->Mediator-> Outcome



Figure 1

Relations between exposure A, mediator M, and outcome Y, and confounders.



# EXPOSURE-MEDIATOR INTERACTION





# **EXPOSURE-MEDIATOR INTERACTION**





Time 3 weeks = aTime 10 weeks =  $a^*$ 

$$\begin{split} \mathsf{E}[\mathsf{Y} \mid \mathsf{a},\mathsf{m},\mathsf{c}] &= \theta_0 + \theta_1 \mathsf{a} + \theta_2 \mathsf{m} + \theta_3 \mathsf{a} \mathsf{m} + \theta_4 \mathsf{c} \\ &= \mathsf{E}[\mathsf{M} \mid \mathsf{a},\mathsf{c}] = \beta_0 + \beta_1 \mathsf{a} + \beta_2 \mathsf{c}. \\ &= \{\theta_1 + \theta_3(\beta_0 + \beta_1 \mathsf{a}^* + \beta_2 \mathsf{c})\}(\mathsf{a} - \mathsf{a}^*) \\ &= \mathsf{I}[\mathsf{E}] = (\beta_1 \theta_2 + \beta_1 \theta_3 \mathsf{a})(\mathsf{a} - \mathsf{a}^*) \end{split}$$

	Insomnia (SCI-8)				Paranoia (GPTS)				Hallucinations (SPEQ)				
	Unadjusted mean		Adjusted difference* (95% CI), d†	p value*	Unadjusted mean		Adjusted difference* (95% CI), d†	p value*	Unadjusted mean		Adjusted difference* (95% CI), d†	p value*	
	Control	Treatment	-		Control	Treatment			Control	Treatment	-		
Week 3	12·34 (5·85)	14·96 (5·80)	2·62 (2·19 to 3·06), 0·61	<0.0001	24·63 (11·82)	22·61 (9·89)	-1·81 (-2·49 to -1·13), 0·15	<0.0001	5.06 (6.89)	4·06 (5·84)	-0·79 (-1·15 to -0·42), 0·12	<0.0001	
Week 10	13·31 (6·45)	18·08 (6·66)	4·78 (4·29 to 5·26), 1·11	<0.0001	23·84 (12·16)	21·06 (9·08)	-2·22 (-2·98 to -1·45), 0·19	<0.0001	4·89 (7·24)	3·12 (5·12)	-1·58 (-1·98 to -1·18), 0·24	<0.0001	
Week 22	14·43 (6·71)	19·27 (7·13)	4·81 (4·29 to 5·33), 1·12	<0.0001	23·84 (12·68)	20·75 (9·19)	-2·78 (-3·60 to -1·96), 0·24	<0.0001	4·71 (7·43)	2·87 (5·45)	-1·56 (-1·99 to -1·14), 0·23	<0.0001	

Data are mean (SD). At week 3, 1398 participants were in the control group and 1044 participants were in the treatment group. At week 10, 1142 participants were in the control group and 733 participants were in the treatment group. At week 22, 971 participants were in the control group and 603 participants were in the treatment group. SCI-8=Sleep Condition Indicator 8-item version. GPTS=Green et al Paranoid Thought Scales. SPEQ=Specific Psychotic Experiences Questionnaire. \*Linear mixed effects model adjusted for gender, student status, week, and interaction of week with randomisation, and including a random effect for student within university. Covariance matrix of within subject measurements was unstructured. †d is standardised effect size (Cohen's d).

Table 2: Primary outcome results

# BINARY OUTCOMES AND MEDIATORS

$$\begin{aligned} &\log \{P(Y = 1 \mid a, m, c)\} = \theta_0 + \theta_1 a + \theta_2 m + \theta_3 am + \theta_4 c \\ &E[M \mid a, c] = \beta_0 + \beta_1 a + \beta_2 c \\ &\log\{OR^{DE}\} \sim = \{\theta_1 + \theta_3(\beta_0 + \beta_1 a + \beta_2 c + \theta_2 \sigma^2)\}(a - a*) + 0.5\theta_3^2 \sigma^2(a^2 - a*^2) \\ &\log\{OR^{IE}\} \sim = (\theta_2 \beta_1 + \theta_3 \beta_1 a)(a - a*) \end{aligned}$$

$$DE = \theta_1(a - a^*) + \theta_3(a - a^*) \frac{\exp(\beta_0 + \beta_1 a^* + \beta'_2 c)}{1 + \exp(\beta_0 + \beta_1 a^* + \beta'_2 c)}$$
$$IE = (\theta_2 + \theta_3 a) \left\{ \frac{\exp(\beta_0 + \beta_1 a + \beta'_2 c)}{1 + \exp(\beta_0 + \beta_1 a + \beta'_2 c)} - \frac{\exp(\beta_0 + \beta_1 a^* + \beta'_2 c)}{1 + \exp(\beta_0 + \beta_1 a^* + \beta'_2 c)} \right\}$$



Mediation Analysis can be used to assess the relative magnitude of pathway and mechanisms by which exposure may affect the outcome